# OnCo record approval-withdrawal (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/approval-withdrawal/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "approval-withdrawal" ;
  schema:name "Indication withdrawal"@en ;
  schema:alternateName "withdrawn"@en, "voluntary withdrawal"@en, "voluntarily withdrawn"@en, "withdrawn indication"@en, "withdrawn from the US market"@en, "withdrawn in the US"@en, "market withdrawal"@en, "indication withdrawn"@en, "re-approved"@en, "re-approval"@en, "reapproved"@en ;
  schema:description "When a drug's approval for a particular cancer is cancelled, usually because the confirmatory trial failed to show benefit, sometimes because of safety. The drug may stay on the market for its other uses, and occasionally an indication is later re-approved on new data."@en ;
  schema:url <https://onco.cc/terms/approval-withdrawal/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Drug_withdrawal> ;
  schema:citation <https://en.wikipedia.org/wiki/Drug_withdrawal> ;
  onco:related <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/confirmatory-trial/>, <https://onco.cc/terms/full-approval/>, <https://onco.cc/terms/odac/>, <https://onco.cc/terms/fdora-2022/>, <https://onco.cc/terms/conditional-approval/>, <https://onco.cc/terms/eu-regulation-726-2004/>, <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/medicare-ced/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:drugs <https://onco.cc/drugs/idelalisib/>, <https://onco.cc/drugs/duvelisib/>, <https://onco.cc/drugs/umbralisib/>, <https://onco.cc/drugs/copanlisib/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/belantamab-mafodotin/> .